Search
Darbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Anacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigational[A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … They also require specialized surgical personnel and facilities, and autologous skin grafting may be needed. Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.
Oxyphenisatin acetate
go.drugbank.com/drugs/DB14627ApprovedWithdrawnOxyphenisatin acetate is the pro-drug of [oxyphenisatin] (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]
Telavancin
go.drugbank.com/drugs/DB06402ApprovedInvestigationalTelavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...
Difluprednate
go.drugbank.com/drugs/DB06781ApprovedInvestigationalDifluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate.
Flumethasone
go.drugbank.com/drugs/DB00663ApprovedVet approvedAs it is a privalate salt, its anti-inflammatory action is concentrated at the site of application.
Mixtures: LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO, LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIOHalothane
go.drugbank.com/drugs/DB01159ApprovedVet approvedWithdrawnAnalgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required.
Categories: NMDA Receptor AntagonistsBunamiodyl
go.drugbank.com/drugs/DB04814ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Dantron
go.drugbank.com/drugs/DB04816ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
Oxeladin
go.drugbank.com/drugs/DB04822ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.